<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03013322</url>
  </required_header>
  <id_info>
    <org_study_id>D.10060224</org_study_id>
    <nct_id>NCT03013322</nct_id>
  </id_info>
  <brief_title>Anticholium® Per Se</brief_title>
  <official_title>Anticholium® Per Se a Randomized, Double-blind, Placebo-controlled, Monocentric Trial on the Adjunctive Use of Physostigmine Salicylate (Anticholium®) in Perioperative Sepsis and Septic Shock</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Heidelberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Heidelberg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Anticholium® per Se is a randomized, double-blind, placebo-controlled, monocentric trial to
      assess whether the CAP can be transferred from bench to bedside. In this pilot study, 20
      patients with perioperative sepsis and septic shock as a result of intra-abdominal infection
      are enrolled. According to randomization, participants are treated with physostigmine
      salicylate (verum group) or 0.9% sodium chloride (placebo group) for up to 5 days. The mean
      Sequential Organ Failure Assessment (SOFA) score during treatment and subsequent intensive
      care of up to 14 days is used as surrogate outcome (primary endpoint). Secondary outcome
      measures include 30- and 90-day mortality. An embedded pharmacokinetics and pharmacodynamics
      study investigates plasma concentrations of physostigmine and its metabolite eseroline.
      Further analyses will contribute to the understanding of the role of various cytokines in the
      pathophysiology of human sepsis. A computer-generated list is used for blocked randomization.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 28, 2015</start_date>
  <completion_date type="Actual">February 18, 2017</completion_date>
  <primary_completion_date type="Actual">February 18, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>mean Sequential Organ Failure Assessment (SOFA) score</measure>
    <time_frame>up to 14 d, assessed 2 h±30 min, 24±2 h, 48±2 h, 72±2 h, 96±2 h, 120±2 h, 6 d±4 h, 7 d±4 h, 8 d±8 h, 9 d±8 h, 10 d±8 h, 11 d±8 h, 12 d±8 h, 13 d±8 h, 14 d±8 h after continuous infusion is commenced</time_frame>
    <description>The mean SOFA score (at least two individual values) during treatment and subsequent intensive care of up to 14 days is used as surrogate outcome in critically ill patients with perioperative sepsis and septic shock due to intra-abdominal infection.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>duration of artificial ventilation</measure>
    <time_frame>up to 90 d</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of intensive care</measure>
    <time_frame>up to 90 d</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length of stay</measure>
    <time_frame>up to 90 d</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30-day mortality</measure>
    <time_frame>30 d</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>90-day mortality</measure>
    <time_frame>90 d</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>arterial blood gas analyses</measure>
    <time_frame>up to 90 d, assessed 2 h±30 min, 24±2 h, 48±2 h, 72±2 h, 96±2 h, 120±2 h, 6 d±4 h, 7 d±4 h, 8 d±8 h, 9 d±8 h, 10 d±8 h, 11 d±8 h, 12 d±8 h, 13 d±8 h, 14 d±8 h, 28 d±8 h, 30 d±8 h, 84 d±8 h, 90 d±8 h after continuous infusion is commenced</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>central venous blood gas analyses</measure>
    <time_frame>up to 90 d, assessed 2 h±30 min, 24±2 h, 48±2 h, 72±2 h, 96±2 h, 120±2 h, 6 d±4 h, 7 d±4 h, 8 d±8 h, 9 d±8 h, 10 d±8 h, 11 d±8 h, 12 d±8 h, 13 d±8 h, 14 d±8 h, 28 d±8 h, 30 d±8 h, 84 d±8 h, 90 d±8 h after continuous infusion is commenced</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>partial pressure of arterial oxygen (PaO2)</measure>
    <time_frame>up to 90 d, assessed 2 h±30 min, 24±2 h, 48±2 h, 72±2 h, 96±2 h, 120±2 h, 6 d±4 h, 7 d±4 h, 8 d±8 h, 9 d±8 h, 10 d±8 h, 11 d±8 h, 12 d±8 h, 13 d±8 h, 14 d±8 h, 28 d±8 h, 30 d±8 h, 84 d±8 h, 90 d±8 h after continuous infusion is commenced</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fraction of inspired oxygen (FiO2)</measure>
    <time_frame>up to 90 d, assessed 2 h±30 min, 24±2 h, 48±2 h, 72±2 h, 96±2 h, 120±2 h, 6 d±4 h, 7 d±4 h, 8 d±8 h, 9 d±8 h, 10 d±8 h, 11 d±8 h, 12 d±8 h, 13 d±8 h, 14 d±8 h, 28 d±8 h, 30 d±8 h, 84 d±8 h, 90 d±8 h after continuous infusion is commenced</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>platelet count</measure>
    <time_frame>up to 90 d, assessed 2 h±30 min, 24±2 h, 48±2 h, 72±2 h, 96±2 h, 120±2 h, 6 d±4 h, 7 d±4 h, 8 d±8 h, 9 d±8 h, 10 d±8 h, 11 d±8 h, 12 d±8 h, 13 d±8 h, 14 d±8 h, 28 d±8 h, 30 d±8 h, 84 d±8 h, 90 d±8 h after continuous infusion is commenced</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>leukocyte count</measure>
    <time_frame>up to 90 d, assessed 2 h±30 min, 24±2 h, 48±2 h, 72±2 h, 96±2 h, 120±2 h, 6 d±4 h, 7 d±4 h, 8 d±8 h, 9 d±8 h, 10 d±8 h, 11 d±8 h, 12 d±8 h, 13 d±8 h, 14 d±8 h, 28 d±8 h, 30 d±8 h, 84 d±8 h, 90 d±8 h after continuous infusion is commenced</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>creatinine</measure>
    <time_frame>up to 90 d, assessed 2 h±30 min, 24±2 h, 48±2 h, 72±2 h, 96±2 h, 120±2 h, 6 d±4 h, 7 d±4 h, 8 d±8 h, 9 d±8 h, 10 d±8 h, 11 d±8 h, 12 d±8 h, 13 d±8 h, 14 d±8 h, 28 d±8 h, 30 d±8 h, 84 d±8 h, 90 d±8 h after continuous infusion is commenced</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urea</measure>
    <time_frame>up to 90 d, assessed 2 h±30 min, 24±2 h, 48±2 h, 72±2 h, 96±2 h, 120±2 h, 6 d±4 h, 7 d±4 h, 8 d±8 h, 9 d±8 h, 10 d±8 h, 11 d±8 h, 12 d±8 h, 13 d±8 h, 14 d±8 h, 28 d±8 h, 30 d±8 h, 84 d±8 h, 90 d±8 h after continuous infusion is commenced</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total bilirubin</measure>
    <time_frame>up to 90 d, assessed 2 h±30 min, 24±2 h, 48±2 h, 72±2 h, 96±2 h, 120±2 h, 6 d±4 h, 7 d±4 h, 8 d±8 h, 9 d±8 h, 10 d±8 h, 11 d±8 h, 12 d±8 h, 13 d±8 h, 14 d±8 h, 28 d±8 h, 30 d±8 h, 84 d±8 h, 90 d±8 h after continuous infusion is commenced</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein</measure>
    <time_frame>up to 90 d, assessed 2 h±30 min, 24±2 h, 48±2 h, 72±2 h, 96±2 h, 120±2 h, 6 d±4 h, 7 d±4 h, 8 d±8 h, 9 d±8 h, 10 d±8 h, 11 d±8 h, 12 d±8 h, 13 d±8 h, 14 d±8 h, 28 d±8 h, 30 d±8 h, 84 d±8 h, 90 d±8 h after continuous infusion is commenced</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>prothrombin time</measure>
    <time_frame>up to 90 d, assessed 2 h±30 min, 24±2 h, 48±2 h, 72±2 h, 96±2 h, 120±2 h, 6 d±4 h, 7 d±4 h, 8 d±8 h, 9 d±8 h, 10 d±8 h, 11 d±8 h, 12 d±8 h, 13 d±8 h, 14 d±8 h, 28 d±8 h, 30 d±8 h, 84 d±8 h, 90 d±8 h after continuous infusion is commenced</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>D-dimer</measure>
    <time_frame>up to 90 d, assessed 2 h±30 min, 24±2 h, 48±2 h, 72±2 h, 96±2 h, 120±2 h, 6 d±4 h, 7 d±4 h, 8 d±8 h, 9 d±8 h, 10 d±8 h, 11 d±8 h, 12 d±8 h, 13 d±8 h, 14 d±8 h, 28 d±8 h, 30 d±8 h, 84 d±8 h, 90 d±8 h after continuous infusion is commenced</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>procalcitonin</measure>
    <time_frame>up to 90 d, assessed 2 h±30 min, 24±2 h, 48±2 h, 72±2 h, 96±2 h, 120±2 h, 6 d±4 h, 7 d±4 h, 8 d±8 h, 9 d±8 h, 10 d±8 h, 11 d±8 h, 12 d±8 h, 13 d±8 h, 14 d±8 h, 28 d±8 h, 30 d±8 h, 84 d±8 h, 90 d±8 h after continuous infusion is commenced</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-6</measure>
    <time_frame>up to 30 d, assessed 2 h±30 min, 24±2 h, 48±2 h, 72±2 h, 96±2 h, 120±2 h, 6 d±4 h, 7 d±4 h, 14 d±8 h, 28 d±8 h, 30 d±8 h after continuous infusion is commenced</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>thrombin-antithrombin complex</measure>
    <time_frame>up to 30 d, assessed 2 h±30 min, 24±2 h, 48±2 h, 72±2 h, 96±2 h, 120±2 h, 6 d±4 h, 7 d±4 h, 14 d±8 h, 28 d±8 h, 30 d±8 h after continuous infusion is commenced</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean blood pressure</measure>
    <time_frame>up to 90 d, assessed 2 h±30 min, 24±2 h, 48±2 h, 72±2 h, 96±2 h, 120±2 h, 6 d±4 h, 7 d±4 h, 8 d±8 h, 9 d±8 h, 10 d±8 h, 11 d±8 h, 12 d±8 h, 13 d±8 h, 14 d±8 h, 28 d±8 h, 30 d±8 h, 84 d±8 h, 90 d±8 h after continuous infusion is commenced</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>frequency of vasopressors</measure>
    <time_frame>up to 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of vasopressors</measure>
    <time_frame>up to 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>frequency of renal replacement therapy</measure>
    <time_frame>up to 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of renal replacement therapy</measure>
    <time_frame>up to 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glasgow Coma Scale (GCS) score</measure>
    <time_frame>up to 90 d, assessed 2 h±30 min, 24±2 h, 48±2 h, 72±2 h, 96±2 h, 120±2 h, 6 d±4 h, 7 d±4 h, 8 d±8 h, 9 d±8 h, 10 d±8 h, 11 d±8 h, 12 d±8 h, 13 d±8 h, 14 d±8 h, 28 d±8 h, 30 d±8 h, 84 d±8 h, 90 d±8 h after continuous infusion is commenced</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Physiology And Chronic Health Evaluation (APACHE) II score</measure>
    <time_frame>up to 90 d, assessed 2 h±30 min, 24±2 h, 48±2 h, 72±2 h, 96±2 h, 120±2 h, 6 d±4 h, 7 d±4 h, 8 d±8 h, 9 d±8 h, 10 d±8 h, 11 d±8 h, 12 d±8 h, 13 d±8 h, 14 d±8 h, 28 d±8 h, 30 d±8 h, 84 d±8 h, 90 d±8 h after continuous infusion is commenced</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Simplified Acute Physiology Score (SAPS) II score</measure>
    <time_frame>up to 90 d, assessed 2 h±30 min, 24±2 h, 48±2 h, 72±2 h, 96±2 h, 120±2 h, 6 d±4 h, 7 d±4 h, 8 d±8 h, 9 d±8 h, 10 d±8 h, 11 d±8 h, 12 d±8 h, 13 d±8 h, 14 d±8 h, 28 d±8 h, 30 d±8 h, 84 d±8 h, 90 d±8 h after continuous infusion is commenced</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>occurrence of side effects</measure>
    <time_frame>up to 6 d, assessed 2 h±30 min, 24±2 h, 48±2 h, 72±2 h, 96±2 h, 120±2 h, 6 d±4 h after continuous infusion is commenced</time_frame>
    <description>nausea or vomiting, clinically relevant changes in heart rate or blood pressure (mainly hypotension), and clinically relevant changes in airway resistance (mainly bronchiospasms as a result of hypersensitivity reactions to the sodium metabisulfite contained in the investigational medicinal product spontaneous breathing: acute dyspnea or artificial ventilation: clinically relevant decline in respiratory volume at constant pressure settings, or clinically relevant incline in peak or inspiratory pressures at constant respiratory volumes)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>microbiological analyses of potential pathogens including susceptibility tests</measure>
    <time_frame>up to 90 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>plasma concentrations of physostigmine</measure>
    <time_frame>up to 6 d, assessed 3±2 min after study med, end of initial ±2 min, 10, 20, 30±2 min, 1 h±10 min, 2 h±30 min, 24, 48, 72, 96, 120±2 h after continuous (end of study med), 10, 20, 30±2 min, 1, 2 h±10 min after end of study med, 6 d ± 4 h after continuous</time_frame>
    <description>determined with a validated high-performance liquid chromatography (HPLC) method</description>
  </other_outcome>
  <other_outcome>
    <measure>plasma concentrations of eseroline</measure>
    <time_frame>up to 6 d, assessed 3±2 min after study med, end of initial ±2 min, 10, 20, 30±2 min, 1 h±10 min, 2 h±30 min, 24, 48, 72, 96, 120±2 h after continuous (end of study med), 10, 20, 30±2 min, 1, 2 h±10 min after end of study med, 6 d ± 4 h after continuous</time_frame>
    <description>determined with a validated high-performance liquid chromatography (HPLC) method</description>
  </other_outcome>
  <other_outcome>
    <measure>acetylcholinesterase activity</measure>
    <time_frame>up to 6 d, assessed 1 h±10 min, 2 h±30 min, 24±2 h, 48±2 h, 72±2 h, 96±2 h, 120±2 h, 6 d±4 h after continuous infusion is commenced</time_frame>
    <description>determined with ChE check mobile (Securetec, Neubiberg, Germany) from remaining material drawn for routine blood gas analyses (arterial samples)</description>
  </other_outcome>
  <other_outcome>
    <measure>butyrylcholinesterase activity</measure>
    <time_frame>up to 6 d, assessed 1 h±10 min, 2 h±30 min, 24±2 h, 48±2 h, 72±2 h, 96±2 h, 120±2 h, 6 d±4 h after continuous infusion is commenced</time_frame>
    <description>determined with ChE check mobile (Securetec, Neubiberg, Germany) from remaining material drawn for routine blood gas analyses (arterial samples)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Shock, Septic</condition>
  <condition>Sepsis</condition>
  <condition>Perioperative Period</condition>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The treatment group receives an infusion of 0.04 mg/kg physostigmine salicylate with a maximum dose of 4 mg. The infusion is administered at 0.4 mg/min (= 1 mL/min = 60 mL/h). The initial dose is followed by a continuous infusion of 0.017 mg/min, i.e. 1 mg/h (= 0.042 mL/min = 2.5 mL/h) for 2-5 days, i.e. 48-120 hours (treatment phase).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo group is treated with 0.9% sodium chloride.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Physostigmine</intervention_name>
    <arm_group_label>Treatment Group</arm_group_label>
    <other_name>Anticholium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isotonic Saline</intervention_name>
    <arm_group_label>Placebo Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          -  Age 18-85 years

          -  APACHE II score &lt;34

          -  Intra-abdominal infection

               -  findings of diffuse peritonitis or a circumscribed abscess

          -  Perioperative sepsis

               -  and secure evidence of infection, clinically backed up or secured
                  microbiologically

               -  ≥2 of the following four criteria:

                    -  fever ≥38.0° C or hypothermia ≤36.0° C secured by rectal intravesical or
                       intravascular measurement

                    -  tachycardia ≥90/min

                    -  tachypnea ≥20/min or hyperventilation secured by arterial blood gas analysis
                       with PaCO2 ≤4.3 kPa or 33 mmHg or mechanical artificial respiration

                    -  leukocytosis ≥12,000/mm³ or leukopenia ≤4000/mm³ or ≥10% immature
                       neutrophils in the differential count

          -  Shock (&lt;24 h duration): necessary use of vasopressors despite adequate fluid
             resuscitation to keep systolic blood pressure ≥90 mmHg or mean blood pressure ≥70 mmHg

          -  No more than one planned and/or one emergency basis/as an emergency procedure
             performed since admission (no repeated revisions)

          -  No infaust prognosis of a primary or concomitant illness, expecting the death within
             the follow-up phase

          -  No do-not-resuscitate order

          -  Written informed consent of full-age patients/their legal guardian to participate
             [written consent (according to AMG § 40 (1) 3b)] and unable to consent adults [§ 41
             (1) 2 AMG)]

        Exclusion criteria

          -  Known hypersensitivity to physostigmine salicylate, sodium metabisulfite, sodium EDTA,
             or any of the other ingredients of Anticholium®

          -  Known contraindications against Anticholium®: gangrene, coronary artery disease

          -  Known absolute contraindications against Anticholium®: myotonic dystrophy;
             depolarization block by depolarizing muscle relaxants; intoxication by &quot;irreversibly
             acting&quot; cholinesterase inhibitors; closed craniocerebral trauma; obstruction in the
             gastrointestinal tract (mechanical constipation); obstruction in the urinary tract
             (mechanical urinary retention)

          -  Known relative contraindications against Anticholium®: bronchial asthma; bradycardia;
             AV-conduction disturbances

          -  Having undergone splenectomy

          -  Having undergone solid organ transplantation

          -  Positive pregnancy test, pregnancy, and lactation

          -  Participation in another clinical trial, according to AMG or the follow-up phase of
             another study, according to AMG
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johannes B Zimmermann, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Heidelberg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Württemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 1, 2017</study_first_submitted>
  <study_first_submitted_qc>January 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2017</study_first_posted>
  <last_update_submitted>January 25, 2018</last_update_submitted>
  <last_update_submitted_qc>January 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Heidelberg</investigator_affiliation>
    <investigator_full_name>Johannes Zimmermann</investigator_full_name>
    <investigator_title>Dr. med. Johannes B. Zimmermann, MSc</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Salicylates</mesh_term>
    <mesh_term>Physostigmine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

